CD274 and head and neck squamous cell carcinoma: • Clinicians should exercise caution interpreting results at the CPS ≥20 cutoff, as PD-L1 IHC 22C3 pharmDx did not meet acceptance criteria for positive percentage agreement and overall percentage agreement in reproducibility studies on HNSCC specimens; however, all criteria were met at the CPS ≥1 cutoff